Donggu Valsartan Tablets 80 mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Donggu Biopharmaceutical Co., Ltd.
MFDS item code 200809435 · Notified 2008.09.11
This product's status changed to Expired on 2024.07.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used for the treatment of essential hypertension and heart failure. It is particularly suitable for heart failure patients who cannot use ACE inhibitors. It also helps reduce the risk of death in patients with decreased left ventricular function after myocardial infarction. Through these effects, it can effectively manage patients' heart health.
1. Essential hypertension Take with water during or between meals. If possible, it is recommended to take this drug at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect appears gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be added. If further blood pressure reduction is required, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years or older): Start treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this drug once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this drug once daily and do not exceed 80 mg daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this drug orally twice daily; this may be increased to 80 mg or 160 mg per dose. A reduction in the diuretic dose should be considered when a diuretic is coadministered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this drug twice daily, followed over several weeks by dose increases to 40 mg, 80 mg, and 160 mg per dose twice daily, depending on the patient's tolerability. Consider dose reduction if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required if creatinine clearance is 10 mL/min or higher. However, this drug should not be administered to patients with creatinine clearance less than 10 mL/min or those on dialysis because there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this drug should preferably not exceed 80 mg. If doses of 80 mg or more daily are administered, consider whether the benefits of dose escalation outweigh the risks. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. It should not be administered to women who are pregnant, may become pregnant, or are breastfeeding. It is also not safe to use in patients with severe liver impairment, cirrhosis, or biliary obstruction. Patients who have had allergic reactions to this medication or similar medications in the past, or patients with hereditary angioedema should not be treated with it. Patients with very poor kidney function or certain kidney diseases should also use caution, and it should not be administered to some kidney disease patients. For diabetic patients with moderate to severe deterioration of kidney function, it should not be used in combination with certain other medications. This medication contains lactose, so patients with lactose intolerance or related genetic disorders should avoid taking it. Elderly patients or those with high blood potassium levels, or patients with mild to moderate liver impairment should start at a low dose and be closely monitored. Patients with heart valve disease or hypertrophic cardiomyopathy, ischemic heart disease, or cerebrovascular disorders should also be careful to avoid excessive drops in blood pressure. This medication can cause hypotension when first administered, so special caution is needed for patients who are especially low in fluid or sodium, and proper action should be taken if hypotension symptoms occur. Care should also be taken when administering this medication to patients undergoing dialysis or those with strict salt restrictions, and those who are within 24 hours before surgery. Caution is required as the combination with other antihypertensives, diuretics, or potassium-sparing diuretics may increase blood potassium levels. Taking this medication with NSAIDs can reduce the antihypertensive effect or worsen kidney function, so caution is necessary. When taken with lithium preparations, lithium levels can increase, leading to toxicity, so serum levels should be regularly monitored. This medication may cause dizziness or drowsiness when driving or operating machinery, so caution is needed. In case of overdose, severe hypotension, loss of consciousness, shock, etc. may occur, and emergency treatment should be sought immediately. Keep out of reach of children and do not transfer to other containers for safety.
headache
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a sealed container. Additionally, it is important to keep it in a cool place below 30 degrees Celsius to maintain its efficacy.
Orange round film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Valsartan 80mg
Tablet · Prescription medication
Donggu Biopharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.